Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224949 · ClinicalTrials.gov registry record
Comparison of ALD, NASH, and Healthy Control Patients
A clinical trial of ALD - Alcoholic Liver Disease, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT03224949 is a study of ALD - Alcoholic Liver Disease that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03224949, a study of ALD - Alcoholic Liver Disease, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in the translation of basic research advances to the clinic. The purpose of the Clinical Core component of the P50 Northern Ohio Alcohol Center (NOAC) is to provide biological samples (plasma/serum, buffy coats, and urine) from patients with different stages of alcoholic liver disease, as well as healthy control subjects, to members of the NOAC. These samples can then be used to test specific hypotheses related to the presence of specific biomarkers in the serum, functional immune activity in PBMCs and/or genetic polymorphisms that may predict severity of disease, short- and long-term morbidity and mortality and/or responsivity to specific therapeutic interventions commonly used in clinical practice. This study is building on the established biorepositories and the diversity of outstanding clinical expertise at the Cleveland Clinic. This biorepository included clinical samples (plasma, serum, buffy coats, and urine) from patients with different stages of ALD and subjects who are heavy drinkers without ALD, recruited from the Cleveland Clinic alcohol use disorder treatment clinic. This study will be responsible for collecting more data to help build the CCF-ALD biorepository via subject recruitment and communication and specimen collection.
Conditions Studied
Interventions
- OTHER Blood draw
Study Locations (1)
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2017-06-19 |
| Est. Completion | 2028-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03224949
The ClinicalTrials.gov registry entry for NCT03224949 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ALD - Alcoholic Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT03224949 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03224949 about?
NCT03224949 is a clinical study titled "Comparison of ALD, NASH, and Healthy Control Patients". The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in the translation of basic research advances to the clinic. The purpose ...
What is the current status of trial NCT03224949?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2017-06-19. Estimated completion is 2028-09-30.
What conditions does trial NCT03224949 study?
This clinical trial studies the following conditions: ALD - Alcoholic Liver Disease.
What interventions are being tested in trial NCT03224949?
The interventions under investigation include: Blood draw (OTHER).
Who is sponsoring clinical trial NCT03224949?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03224949 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.